Bernstein Raises Price Target for DexCom to $86.00

sábado, 10 de enero de 2026, 9:18 pm ET1 min de lectura

Bernstein analyst Lee Hambright has maintained an "Outperform" rating for DexCom (DXCM) and raised the price target from $84.00 to $86.00, representing a 2.38% increase. The company designs and commercializes continuous glucose monitoring systems for diabetic patients, with a focus on integrating with insulin pumps for automatic insulin delivery. The average target price for DXCM is $86.80, indicating a potential 29.16% upside from the current price of $67.21.

Bernstein Raises Price Target for DexCom to $86.00

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios